Overview

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Hydrochlorothiazide
Ramipril